Endo Pharma (RxKinetix) Enter PIII Trials

Posted in CO Private: RxKinetix, CO Pub Rel: Endo Pharma

You may recall a little over a year ago Endo Pharmaceuticals (NASDAQ: ENDP) acquired RxKinetix whose lead product was RK-0202, a topical oral-rinse with the active ingredient formulated in its proprietary ProGelz® drug delivery platform and was in Phase II. It sounds as if great progress is being made on RK-0202 which subsequently has become [...]

2502007-11-08+06%3A07%3A00admin

Oct

2006

RxKinetix: The Hits Keep Coming

Posted in CO Private: RxKinetix

Congratulations to Harry Ross and the entire RxKinetix team on the Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) deal. The disclosed terms indicate Endo Pharma will pay a $20M up-front fee and will follow on with up to an additional $95M in clinical development and regulatory milestone payments. Early indications are that RxKinteix, like Myogen, will [...]

124RxKinetix%3A+The+Hits+Keep+Coming2006-10-13+16%3A03%3A00admin

Jul

2005

RxKinetix – Dynamic Drug Delivery Technologies

Posted in CO Private: RxKinetix

Traveling further down the Boulder Turnpike bio corridor leads one to the steps of RxKinetix, a specialty pharmaceutical company, who is focused upon a proprietary platform of drug delivery technologies. Under the leadership of Harry Ross, MD, President and CEO, a diverse portfolio of pre-clinical and clinical opportunities has been developed. The lead product, RK-0202 [...]